Background: Biliary tract cancer (BTC) is a highly lethal disease for which the best available therapy remains undetermined. The mammalian target of rapamycin (mTOR) pathway is up-regulated in several cancers, including BTC, and preclinical evidence indicates that mTOR inhibition may be effective in the treatment of BTC. We sought to evaluate the activity and tolerability of the mTOR inhibitor RAD001-everolimus-in patients with BTC progressing after prior chemotherapy.
introduction
Biliary tract cancer (BTC), which encompasses cholangiocarcinoma (CC) and gallbladder carcinoma (GBC), is a disease with high mortality, limited treatment options and few significant improvements in the therapeutic strategy over the last 10-20 years. Currently, tumour resection is the only potential cure for BTC. However, most BTCs are diagnosed at advanced stages, when tumour is unresectable. Five-year survival rates are <5%-10% for advanced BTC [1] , and the median survival of patients with advanced disease is frequently <1 year [2] . Chemotherapeutic agents currently used for the treatment of BTC include gemcitabine, 5 fluorouracil (5-FU), mitomycin C and platinum analogues [2] . Objective response rates (ORR) to most of these drugs range from 0% to 40%, with no complete remissions [3] . In most cases, treatment after disease progression consists of palliative care, with only 25% of patients receiving further chemotherapy [4] . More effective strategies for the treatment of BTC are needed to improve the prognosis and quality of life (QoL) of BTC patients.
RAD001 (everolimus) is a mammalian target of rapamycin (mTOR) inhibitor currently indicated for the treatment of advanced breast cancer, neuroendocrine tumours of pancreatic origin and renal cell carcinoma [5] . The mTOR pathway, which plays a key role in cell growth, proliferation and survival, is known to be up-regulated in many cancer types, including extrahepatic CC [6] .
In transgenic mouse models of GBC, mTOR inhibition has yielded promising results [7] . The mTOR status was found to be an independent prognostic factor in patients with BTC, overall survival being significantly shorter in patients with m-TORpositive tumours [8] . We undertook the present study to assess the activity and tolerability of everolimus in patients with BTC progressing after prior chemotherapy.
patients and methods

study design
This was an open-label, single-arm, multicentre phase II study in eight sites in Italy (EUDRACT 2008-007152-94). The study was conducted according to ICH/GCP guidelines and the Declaration of Helsinki and approved by the Ethic Committees of participating Centres. All patients provided written informed consent.
eligibility criteria
Eligible participants were adult patients (age 18-75 years) with histologically or cytologically confirmed locally advanced, metastatic or recurrent BTC that had progressed despite previous chemotherapy and who had at least one measurable site of disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [9] and no indication to surgery or radiotherapy for locally advanced disease. Only patients who had received no more than one previous systemic chemotherapy regimen were enrolled. Adjuvant chemotherapy and/or radiotherapy were not considered as firstline chemotherapy. Further inclusion criteria are provided as supplementary material, available at Annals of Oncology online.
treatment and dose modifications
Everolimus was administered orally at a daily dose of 10 mg continuously (28-day cycles). Therapy was continued from day 1 until progression of disease, unacceptable toxicity or discontinuation from study drug for any other reason. Thereafter, patients were followed-up. Dose adjustments were allowed in patients unable to tolerate the protocol-specified dosing schedule. If toxicity was tolerable to the patient, the initial dose was maintained. Dose reductions for toxicity were as follows: dose level 1, 5 mg daily; and dose level 2, 5 mg every other day.
assessments
Baseline evaluations included a complete history and physical examination; ECOG performance status; complete blood count, coagulation parameters, biochemical measurements and fasting lipid profile; pregnancy test in women of childbearing potential; electrocardiogram and chest X-ray. Laboratory assessments were repeated every 2 weeks and at study end. Tumour measurement was carried out by computed tomography and/or magnetic resonance imaging of the abdomen, pelvis and chest before initiation of treatment and subsequently every 8 weeks. Tumour response was assessed using the RECIST criteria version 1.1 [9] .
Safety was monitored throughout the study and for 28 days after discontinuation of study drug. Adverse events (AEs) terms were classified by Primary System Organ Class (SOC) according to the MedDRA thesaurus version 12 [10] . All patients were assessed for toxicity as per the NCI Common Toxicity Criteria, version 3. Survival was recorded every 2 months for at least 1 year after enrolment of the last patient.
QoL was assessed with the EORTC QLQ-C30 questionnaire [11] at baseline, every 8 weeks and at study end.
activity end points
The two primary activity end points were disease control rate (DCR) and ORR, which were assessed hierarchically. The primary variable for the definition of the DCR was the overall objective response (OOR) at the 8-week assessment, according to RECIST criteria. DCR was calculated as the Secondary activity end points were progression-free survival (PFS), overall survival (OS), and time-to-progression (TTP). PFS was defined as the time from date of the first everolimus dose to the date of the event, defined as the first documented progression or death due to any cause. In the case of no event, PFS was censored at the date of last adequate tumour assessment. OS was defined as the time from date of the first everolimus dose to the date of death for any cause. If a patient was not known to have died, survival was censored at the date of last contact. TTP was defined as time from date of the first everolimus dose to the date of event (first documented progression or death due to the underlying cancer). In the case of no event, time to progression was censored at the date of last adequate tumour assessment.
statistical analysis
A Simon optimum two-stage design was used [12] . The stopping rule was based exclusively on DCR. A DCR of 5% or lower precluded further study, whereas a DCR of 20% or higher would be considered sufficiently promising to warrant further study. Assuming a type I error rate of 10% and a power of 90%, a total of 12 patients were enrolled in the first stage, which required at least one patient achieving disease control to proceed to the second stage. An additional 25 assessable patients would be enrolled in the second stage, giving a total of 37 assessable patients. If ≥3 patients achieved disease control, everolimus would be considered active and worthy of further testing. Patients who experienced progression or death from progressive disease before week 8 were considered as failures in the DCR. All data were considered for patients who had received at least one dose of study drug [intent-totreat (ITT) population]. Patient withdrawals due to AEs or toxicity before the 8-week response evaluation were considered as treatment failures. The Kaplan-Meier curves were estimated for the PFS, OS and TTP.
Continuous variables were summarized by descriptive statistics. Categorical variables were summarized using counts of patients and percentages. Comparisons were carried out with Student's paired t-test. Statistical significance was set at P < 0.05. Statistical analyses were carried out with SAS System (version 9.2, Cary, NC). Table 1 . Thirty-seven patients (94.9%) had a histological or cytological diagnosis of CC, while two (5.1%) had GBC. At diagnosis, 8 patients (20.5%) had stage II disease, 3 (7.7%) had stage III and 28 (71.8%) had stage IV. Thirty-one (79.5%) patients had ECOG 0, five (12.8%) ECOG 1 and three (7.7%) ECOG 2. At study enrolment, all patients had received previous chemotherapy. The combination of gemcitabine and oxaliplatin (GEMOX) was the most common first-line chemotherapy regimen.
treatment exposure
The median compliance was 92.9% (range 50-100%). The median exposure to study drug was 67.5 days (range 15-674 days). Of the 39 assessable patients (ITT population), 36 discontinued the study drug because of disease progression. One patient withdrew consent after 12 weeks and two patients died for the onset of adverse events after 8 weeks of treatment (deaths: 11 and 14 weeks).
activity
One patient was excluded from the analysis of DCR due to missing data on tumour response at week 8. Of the 38 assessable patients, one patient (2.6%) had a PR and 16 patients (42.1%) showed SD (DCR 44.7%) at week 8 (supplementary Table S1 , available at Annals of Oncology online). Twenty-one patients (55.3%) had disease progression at week 8. The ORR was 5.1%, with one patient showing a PR at 2 months (59-year-old male with GBC; PFS 8.5 months and OS 10.1 months) and one patient showing CR at 4, 6 and 8 months (57-year-old male with intrahepatic CC; PFS 10 months and OS 17 months).
The median (95% CI) PFS in the ITT population was 3.2 (1.8-4.0) months ( Figure 1A) . The proportion of progressionfree patients was 51.3% (34. 8-65.6 Table S2 , available at Annals of Oncology online). Percentile analysis showed that onequarter of patients had an OS >15.3 months.
The median TTP in the ITT population was 2.0 (1.7-3.7) months.
safety
The total number of AEs in the safety population (n = 39) was 384; 261 of which (67.9%) were considered as treatment-related (Table 2) . Overall, the most common AEs were asthenia (43.6%), thrombocytopenia (35.9%), pyrexia (30.8%) and The most common grade 3-4 toxicities were hyperbilirubinaemia (15.4%), elevated alanine aminotransferase (12.8%), hypocalcaemia (12.8%), elevated alkaline phosphatase (10.3%), thrombocytopaenia (10.3%) and hyperglycaemia (10.3%). In total, 21 grade 4 AEs were reported; six of these, occurring in three patients (23.1% of patients with grade 4 toxicity), were classified as probably (thrombocytopenia, pneumonia, anorexia, nausea and vomiting), or certainly (stomatitis) related to study drug. Two patients (5.1%) died due to an AE (both for cachexia), but those events were not considered drug-related. Dose reduction due to AEs was required in two patients (one for neutropenia and one for hypersensitivity).
QoL and performance status
Data on QoL at baseline and study end were available for 19 patients (48.7%). There was a trend towards a decrease from baseline in global health status, physical functioning, role functioning and emotional functioning and a statistically significant, moderate improvement in fatigue (P = 0.039). A small but significant (P = 0.030) deterioration was observed in the pain subscale. No changes were observed in the remaining QLQ-C30 items. With respect to PS, at study end, data were available for 26 patients, 22 of whom (84.6%) had ECOG 0-2 and 4 (15.4%) had ECOG ≥3. discussion BTC is a highly lethal cancer for which the best available chemotherapy remains to be determined. In a large meta-analysis of clinical trials of chemotherapy in advanced BTC, the overall OS for all patients included in the survival analysis (n = 1543) was 8.2 months, with a tumour control rate of 57.3% (n = 2386) [13] . At present, gemcitabine-and platinum-containing regimens appear to be the most effective first-line treatment for advanced BTC, with reported median OSs of 9.5-11.7 months [14] . In contrast, there is an urgent need to establish an effective secondline treatment to improve survival of BTC patients.
The results of the present study support the role of mTOR as a potential therapeutic target in BTC. The 44.7% DCR at 8 weeks, along with the median PFS, TTP and OS of ∼3, 2 and 7.2 months, respectively, indicate that everolimus is active in patients with BTC progressing despite previous chemotherapy. Noteworthy, OS data and the percentile analysis seem to suggest that patients who are still alive after the first months of therapy present a prolonged OS, with 32.4% and 25% of patients still alive after 12 and 15 months of therapy, respectively. This finding suggests that proper selection of patients eligible to everolimus therapy could maximize the clinical benefits of the drug. The identification of predictive biomarkers of response to everolimus could help optimize the management of BTC patients, and could be the aim of future studies.
Previously evaluated second-line chemotherapy regimens include the combination of 5-FU, doxorubicin and mitomycin C, gemcitabine as a single agent and the oral fluoropyrimidine S-1 [15] [16] [17] . In these trials, the average DCR was ∼43%, with a median TTP of ∼2 months, a median OS of 4-7 months and no patient showing CR. Recently, a retrospective study analysed the efficacy of second-line chemotherapy in advanced BTC, reporting DCRs and SD of 43% and 34%, respectively, and the median PFS and OS of 2.8 and 7.5 months, respectively [4] .
Although a comparison with previous studies is difficult due to different design and patient populations, in the present study, everolimus treatment resulted in longer OS when compared with previous trials on second-line chemotherapy, complete tumour response in one patient at 4, 6 and 8 months and partial response in one patient at 2 months. Furthermore, 42.1% of patients had SD at 2 months.
Targeting the mTOR pathway may represent a novel and effective strategy for the treatment of BTC. Although the genetics of BTC are highly heterogeneous, there is evidence that the mTOR pathway is involved either directly or indirectly in CC tumorigenesis [18] , and activation of this pathway may negatively impact the prognosis of patients with BTC [8] . Inhibition of Table 2 . Total adverse events by system organ class (SOC) and severity and proportion of adverse events with a suspected relationship with everolimus experienced by ≥5% of patients (safety population, n = 39) [19, 20] . Everolimus was able to induce a 50% reduction in cell growth of human extrahepatic CC and GBC cell lines, and the combination of everolimus with gemcitabine had the strongest synergistic effect on extrahepatic cell lines when compared with the combination of gemcitabine with a VEGF-inhibitor, allowing a significant reduction in the median gemcitabine dose [21] . A single-arm, phase I study designed to determine the maximally tolerated dose of everolimus plus gemcitabine and to obtain pilot data on toxicity and efficacy outcomes in patients with advanced refractory CC/GBC is currently ongoing [22] . In the present study, drug-related toxicity was observed in 92.3% of patients, with a spectrum of toxicities that was similar to that observed with everolimus in other cancers [23, 24] . Overall, everolimus had not any marked effect on QoL.
The patient sample in this study was relatively small. However, this reflects the modest incidence of the disease in the overall population; in addition, many BTC patients die or require only supportive care after the first-line treatment. We used the RECIST criteria to evaluate DCR, PFS and TTP. These criteria may not take into account the cytostatic effect of everolimus, since they are more focused on variations in tumour size. Lastly, we did not report data on immunohistochemistry (IHC) assessments: IHC samples were available only for 11 patients, all treated in a single Centre (Istituto Nazionale Tumori, Milan, Italy) and therefore not representative of the entire study population.
In conclusion, everolimus demonstrated a favourable toxicity profile and promising anti-tumour activity as a second-line therapy in BTC patients. Larger trials are needed to better establish the role of everolimus in the treatment of BTC and identify prognostic biomarkers predictive of response to targeted therapies. 
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